MCID: PTY001
MIFTS: 44

Pityriasis Rosea

Categories: Skin diseases

Aliases & Classifications for Pityriasis Rosea

MalaCards integrated aliases for Pityriasis Rosea:

Name: Pityriasis Rosea 12 36 44 15 17 70 32
Pityriasis Circinata 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8892
KEGG 36 H01660
ICD9CM 34 696.3
MeSH 44 D017515
NCIt 50 C26855
SNOMED-CT 67 156373006
ICD10 32 L42
UMLS 70 C0032026

Summaries for Pityriasis Rosea

KEGG : 36 Pityriasis rosea (PR) is an acute exanthem, which prevalently affects children and young adults. The cause of PR is uncertain but epidemiological (seasonal variation and clustering in communities) and clinical features suggest an infective agent. Light and electron microscopy findings suggest infection with human herpesviruses 6 and 7 (HHV-6/7). HHV-6 and HHV-7 may also interact with each other, explaining recurrences and atypical presentations. PR is self limiting and resolves within one to three months. It typically starts with the development of a large erythematous scaly plaque also called the herald patch or mother patch on trunk or neck, which is followed by an eruption of multiple secondary small erythematous scaly lesions located predominantly on the trunk and following the lines of cleavage on the back (Christmas tree or inverted fir tree appearance). Collarette scaling is seen typically. The eruption is usually preceded by a prodrome of sore throat, gastrointestinal disturbance, fever, and arthralgia. A case of PR is diagnosed mainly on clinical grounds. A biopsy is needed in atypical cases, and it mainly helps in excluding other differentials rather than diagnosing PR as the histopathological examination in a case of PR is relatively nonspecific and resembles a subacute or chronic dermatitis. As PR is a self-limiting disorder, most patients just need to be counseled regarding the natural course of the disease instead of putting them on an aggressive treatment protocol. Most patients would just need emollients, antihistaminics, and sometimes topical steroids to control pruritus.

MalaCards based summary : Pityriasis Rosea, also known as pityriasis circinata, is related to herpes zoster and geographic tongue. An important gene associated with Pityriasis Rosea is CX3CL1 (C-X3-C Motif Chemokine Ligand 1), and among its related pathways/superpathways are Innate Immune System and Class I MHC mediated antigen processing and presentation. The drugs Tacrolimus and Petrolatum have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and bone marrow, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Disease Ontology : 12 A dermatitis that is characterized by an initial large round spot on the chest, abdomen, or back, often referred to as a herald patch, that is usually followed within a week by a distinctive pattern of similar but smaller papules on the torso, arms, and legs.

Wikipedia : 73 Pityriasis rosea is a type of skin rash. Classically, it begins with a single red and slightly scaly... more...

Related Diseases for Pityriasis Rosea

Diseases related to Pityriasis Rosea via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 253)
# Related Disease Score Top Affiliating Genes
1 herpes zoster 30.7 HLA-DRB1 HLA-B HLA-A
2 geographic tongue 30.5 HLA-DQB1 HLA-A
3 psoriasis 30.5 HLA-DRB1 HLA-C HLA-B HLA-A
4 kaposi sarcoma 30.1 HLA-C HLA-B HLA-A
5 aphthous stomatitis 30.1 HLA-DRB1 HLA-B HLA-A
6 seborrheic dermatitis 29.9 CD1E CD1A
7 myocarditis 29.9 HLA-DRB4 HLA-DQB1 HLA-B
8 pharyngitis 29.9 HLA-DRB1 CD1A
9 behcet syndrome 29.8 HLA-DRB1 HLA-C HLA-B HLA-A
10 aplastic anemia 29.7 HLA-DRB1 HLA-DQB1 HLA-B HLA-A
11 rubella 29.6 HLA-DRB1 HLA-DQB1 HLA-C HLA-B HLA-A
12 leprosy 3 29.0 HLA-DRB1 HLA-B HLA-A CD1E CD1A
13 exanthem 10.8
14 skin disease 10.8
15 pustulosis of palm and sole 10.6
16 syphilis 10.6
17 secondary syphilis 10.5
18 lichen planus 10.5
19 dermatitis 10.4
20 erythema multiforme 10.4
21 dowling-degos disease 1 10.3
22 herpes simplex 10.3
23 guttate psoriasis 10.3
24 limbic encephalitis with lgi1 antibodies 10.3 HLA-DRB1 HLA-DQB1
25 autoimmune polyglandular syndrome type 3 10.3 HLA-DRB1 HLA-DQB1
26 idiopathic hypersomnia 10.3 HLA-DRB1 HLA-DQB1
27 hypersomnia 10.3 HLA-DRB1 HLA-DQB1
28 narcolepsy 2 10.3 HLA-DRB1 HLA-DQB1
29 latent autoimmune diabetes in adults 10.3 HLA-DRB1 HLA-DQB1
30 occupational asthma 10.3 HLA-DRB1 HLA-DQB1
31 primary adrenal insufficiency 10.3 HLA-DRB1 HLA-DQB1
32 recurrent respiratory papillomatosis 10.3 HLA-DRB1 HLA-DQB1
33 beryllium disease 10.3 HLA-DRB1 HLA-DQB1
34 echinococcosis 10.3 HLA-DRB1 HLA-B
35 apple allergy 10.3 HLA-DRB1 HLA-DQB1
36 chronic beryllium disease 10.3 HLA-DRB1 HLA-DQB1
37 rheumatoid vasculitis 10.3 HLA-DRB1 CX3CL1
38 ige responsiveness, atopic 10.3
39 dermatitis, atopic 10.3
40 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.3
41 urticaria 10.3
42 hepatitis c 10.3
43 dermatophytosis 10.3
44 pityriasis lichenoides 10.3
45 metal allergy 10.3 HLA-DRB1 HLA-DQB1
46 focal epithelial hyperplasia 10.3 HLA-DRB1 HLA-DQB1
47 pediatric multiple sclerosis 10.3 HLA-DRB1 HLA-DQB1
48 podoconiosis 10.3 HLA-DRB1 HLA-DQB1
49 pemphigoid 10.3 HLA-DRB1 HLA-DQB1
50 osteonecrosis of the jaw 10.3 HLA-DRB1 HLA-DQB1

Graphical network of the top 20 diseases related to Pityriasis Rosea:



Diseases related to Pityriasis Rosea

Symptoms & Phenotypes for Pityriasis Rosea

GenomeRNAi Phenotypes related to Pityriasis Rosea according to GeneCards Suite gene sharing:

26 (show top 50) (show all 63)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-103 11.17 HLA-A HLA-B HLA-C
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-110 11.17 HLA-A HLA-B HLA-C
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-113 11.17 HLA-DRB3
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-119 11.17 HLA-DRB4
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-127 11.17 HLA-DRB4
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-128 11.17 HLA-DRB1
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-14 11.17 HLA-C
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-156 11.17 HLA-A HLA-B HLA-C
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-174 11.17 HLA-DRB4
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-178 11.17 HLA-A HLA-B HLA-C
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-19 11.17 HLA-A HLA-B HLA-C
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-2 11.17 HLA-DRB4
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-202 11.17 HLA-C
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-26 11.17 HLA-DRB4
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-31 11.17 HLA-DRB4 HLA-A HLA-B HLA-C
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-40 11.17 HLA-DRB3
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-58 11.17 HLA-DRB5
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 11.17 HLA-DRB1
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-7 11.17 HLA-A HLA-B HLA-C
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-80 11.17 HLA-DRB1 HLA-DRB3
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-87 11.17 HLA-DRB4
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 11.17 HLA-C
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-95 11.17 HLA-C
24 Increased shRNA abundance (Z-score > 2) GR00366-A-104 10.15 HLA-DRB3
25 Increased shRNA abundance (Z-score > 2) GR00366-A-109 10.15 HLA-DRB5
26 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.15 HLA-A HLA-B HLA-C
27 Increased shRNA abundance (Z-score > 2) GR00366-A-12 10.15 HLA-DRB1 HLA-DRB4
28 Increased shRNA abundance (Z-score > 2) GR00366-A-124 10.15 HLA-C
29 Increased shRNA abundance (Z-score > 2) GR00366-A-130 10.15 HLA-DRB4
30 Increased shRNA abundance (Z-score > 2) GR00366-A-132 10.15 HLA-DRB3
31 Increased shRNA abundance (Z-score > 2) GR00366-A-137 10.15 HLA-DRB1 HLA-DRB4
32 Increased shRNA abundance (Z-score > 2) GR00366-A-139 10.15 HLA-DRB3
33 Increased shRNA abundance (Z-score > 2) GR00366-A-14 10.15 HLA-DRB5
34 Increased shRNA abundance (Z-score > 2) GR00366-A-142 10.15 HLA-DRB1 HLA-DRB4
35 Increased shRNA abundance (Z-score > 2) GR00366-A-148 10.15 HLA-DRB4
36 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.15 HLA-C
37 Increased shRNA abundance (Z-score > 2) GR00366-A-150 10.15 HLA-DRB4
38 Increased shRNA abundance (Z-score > 2) GR00366-A-153 10.15 HLA-DRB3
39 Increased shRNA abundance (Z-score > 2) GR00366-A-162 10.15 HLA-C
40 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.15 HLA-DRB1 HLA-DRB3
41 Increased shRNA abundance (Z-score > 2) GR00366-A-170 10.15 HLA-DRB3
42 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.15 HLA-DRB5
43 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.15 HLA-DRB1 HLA-DRB3 HLA-DRB4 HLA-DRB5
44 Increased shRNA abundance (Z-score > 2) GR00366-A-178 10.15 HLA-DRB5
45 Increased shRNA abundance (Z-score > 2) GR00366-A-179 10.15 HLA-DRB3
46 Increased shRNA abundance (Z-score > 2) GR00366-A-185 10.15 HLA-DRB1 HLA-DRB3 HLA-DRB4
47 Increased shRNA abundance (Z-score > 2) GR00366-A-196 10.15 HLA-DRB1 HLA-DRB3 HLA-DRB4
48 Increased shRNA abundance (Z-score > 2) GR00366-A-211 10.15 HLA-DRB3
49 Increased shRNA abundance (Z-score > 2) GR00366-A-212 10.15 HLA-DRB4
50 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.15 HLA-DRB4

Drugs & Therapeutics for Pityriasis Rosea

Drugs for Pityriasis Rosea (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 29)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643 439492
2
Petrolatum Approved, Investigational Phase 4 8009-03-8
3
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 5280453 134070
4 Immunosuppressive Agents Phase 4
5 Dermatologic Agents Phase 4
6 Calcineurin Inhibitors Phase 4
7 Vasoconstrictor Agents Phase 4
8 Hormones Phase 4
9 Emollients Phase 4
10 Calcium, Dietary Phase 4
11
Calcium Nutraceutical Phase 4 7440-70-2 271
12
Pimecrolimus Approved, Investigational Phase 2, Phase 3 137071-32-0 6447131 17753757
13 Analgesics, Non-Narcotic Phase 2, Phase 3
14 Analgesics Phase 2, Phase 3
15 Antirheumatic Agents Phase 2, Phase 3
16 Anti-Inflammatory Agents Phase 2, Phase 3
17 Sunscreening Agents Phase 2, Phase 3
18 Anti-Inflammatory Agents, Non-Steroidal Phase 2, Phase 3
19
Vitamin D Approved, Nutraceutical, Vet_approved 1406-16-2
20 Immunologic Factors
21 Nutrients
22 Micronutrients
23 Trace Elements
24 Vitamins
25 Calciferol
26 Immunoglobulins
27 Antibodies
28 Immunoglobulins, Intravenous
29 Immunoglobulin E

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 A Double Blind Randomized Trial, Placebo-controled of 0.0003% Calcitriol Ointment Versus 0.1% Tacrolimus Ointment in the Treatment of Pityriasis Alba Completed NCT01388517 Phase 4 Tacrolimus;Calcitriol;Petrolatum
2 Efficacy of Topical Pimecrolimus in the Treatment of Pityriasis Alba: A Randomized Placebo-controlled Trial Unknown status NCT03834935 Phase 2, Phase 3 Elidel (pimecrolimus 1%);Cold Cream
3 Serum 25(OH) Vitamin D and Total Serum Immunoglobulin E Levels in Patients With Pityriasis Alba Active, not recruiting NCT03443765

Search NIH Clinical Center for Pityriasis Rosea

Inferred drug relations via UMLS 70 / NDF-RT 51 :


methdilazine
Methdilazine hydrochloride

Cochrane evidence based reviews: pityriasis rosea

Genetic Tests for Pityriasis Rosea

Anatomical Context for Pityriasis Rosea

MalaCards organs/tissues related to Pityriasis Rosea:

40
Skin, T Cells, Bone Marrow, Myeloid, Tongue

Publications for Pityriasis Rosea

Articles related to Pityriasis Rosea:

(show top 50) (show all 676)
# Title Authors PMID Year
1
Pityriasis rosea as a leading manifestation of COVID-19 infection. 61
33258224 2021
2
Human herpesvirus-6, -7, and Epstein-Barr virus reactivation in pityriasis rosea during COVID-19. 61
32970319 2021
3
Symmetric blaschkoid pityriasis rosea in a child. 61
33742484 2021
4
Public interest in dermatologic symptoms, conditions, treatments, and procedures during the COVID-19 pandemic: Insights from Google Trends. 61
33595849 2021
5
Pityriasis Rosea-like Eruption Induced by Imatinib in a Patient With a Gastrointestinal Stromal Tumor. 61
33675726 2021
6
A convolutional neural network architecture for the recognition of cutaneous manifestations of COVID-19. 61
33604961 2021
7
A multiplex real-time PCR quantitation of human herpesvirus-6, 7, 8 viruses: application in blood transfusions. 61
33602271 2021
8
Dermoscopy in general dermatology (non-neoplastic dermatoses): pitfalls and tips. 61
33533022 2021
9
Cutaneous manifestations of COVID-19. 61
33560783 2021
10
Pityriasis rosea in otherwise asymptomatic confirmed COVID-19-positive patients: A report of 2 cases. 61
33195784 2021
11
Pregnancy complications associated with pityriasis rosea: A multicenter retrospective study. 61
33422632 2021
12
L-lysine therapy to control the clinical evolution of pityriasis rosea: Clinical case report and literature review. 61
33326128 2021
13
Dermoscopy Differentiates Guttate Psoriasis from a Mimicker-Pityriasis Rosea. 61
33614216 2021
14
Dermoscopic characterization of guttate psoriasis, pityriasis rosea, and pityriasis lichenoides chronica in dark skin phototypes: An observational study. 61
33277950 2021
15
SARS-CoV-2 spike protein positivity in pityriasis rosea-like and urticaria-like rashes of COVID-19. 61
33511657 2021
16
Pigmented purpuric dermatosis: Ten years of experience in a tertiary hospital and awareness of mycosis fungoides in differential diagnosis. 61
33368594 2020
17
Multicenter study evaluating the impact of COVID-19 outbreak on dermatology outpatients in Turkey. 61
33135831 2020
18
Differentiation of inflammatory papulosquamous skin diseases based on skin biophysical and ultrasonographic properties: A decision tree model. 61
33037158 2020
19
Pityriasis rosea during omalizumab treatment for chronic spontaneous urticaria. 61
33009684 2020
20
Relative changes in the pattern of diseases presenting in dermatology outpatient clinic in the era of the COVID-19 pandemic. 61
32869938 2020
21
Emergency dermatology: Three-month experience from an Italian academic outpatient clinic during lockdown for COVID-19 pandemic. 61
33037759 2020
22
Case of generalized annular pustular psoriasis that has progressed from terbinafine-induced pityriasis rosea-like eruption. 61
33174279 2020
23
Histological and immunohistopathological differentiation between guttate psoriasis and pityriasis rosea. 61
33020906 2020
24
Pityriasis rosea-like eruption revealing COVID-19. 61
33216971 2020
25
Pityriasis rosea and COVID-19. 61
33205836 2020
26
Atypical Palmoplantar Pityriasis Rosea. 61
33130012 2020
27
Anetodermic lesions following pityriasis rosea and impetigo. 61
30229641 2020
28
Pityriasis Rosea Unilateralis: A Rare Presentation in Two Females. 61
33235856 2020
29
Pityriasis Rosea: An Updated Review. 61
32964824 2020
30
HHV 6-7 reactivation causing Pityriasis Rosea and labyrinthitis: A case report. 61
32553563 2020
31
[Pityriasis rosea Gibert type rash in an asymptomatic patient that tested positive for COVID-19]. 61
32654832 2020
32
Pityriasis rosea Gibert type rash in an asymptomatic patient that tested positive for COVID-19. 61
32923675 2020
33
Pityriasis rosea as a cutaneous manifestation of COVID-19 infection. 61
32359180 2020
34
An Atypical Presentation of Pityriasis Rosea Localized to the Extremities. 61
32944477 2020
35
Childhood Pityriasis Rosea With Multiple Herald Patches. 61
32963916 2020
36
The clinics of HHV-6 infection in COVID-19 pandemic: Pityriasis rosea and Kawasaki disease. 61
32475003 2020
37
Dermoscopy in differential diagnosis of inflammatory dermatoses and mycosis fungoides. 61
32406102 2020
38
Change of the diagnostic distribution in applicants to dermatology after COVID-19 pandemic: What it whispers to us? 61
32530503 2020
39
Pityriasis Rosea: Risk and Treatment During Pregnancy. 61
32208015 2020
40
Unilateral pityriasis rosea. 61
31646609 2020
41
Acute exanthemas: a prospective study of 98 adult patients with an emphasis on cytokinic and metagenomic investigation. 61
31127953 2020
42
Pityriasis rosea and other infectious eruptions during pregnancy: Possible life-threatening health conditions for the fetus. 61
32197740 2020
43
Histopathologic features distinguishing secondary syphilis from its mimickers. 61
31306731 2020
44
Dermatologic Problems Commonly Seen by the Allergist/Immunologist. 61
31351991 2020
45
The rash with mucosal ulceration. 61
32197747 2020
46
Erythematous Papular Rash: A Dermatological Feature of COVID-19. 61
32665937 2020
47
Reply to: comment on “Is there a relationship between environmental factors and pityriasis rosea?” 61
31854957 2019
48
Is there a relationship between environmental factors and pityriasis rosea? Reply to Singh et al. 61
31854956 2019
49
Evaluation of thiol/disulfide homeostasis in patients with pityriasis rosea. 61
31092070 2019
50
Inverse Pityriasis Rosea. 61
31729335 2019

Variations for Pityriasis Rosea

Expression for Pityriasis Rosea

Search GEO for disease gene expression data for Pityriasis Rosea.

Pathways for Pityriasis Rosea

Pathways related to Pityriasis Rosea according to GeneCards Suite gene sharing:

(show all 34)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.88 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1 HLA-C
2
Show member pathways
13.37 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1 HLA-C
3
Show member pathways
13.29 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1 HLA-C
4
Show member pathways
13.04 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1
5
Show member pathways
12.91 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1 HLA-C
6
Show member pathways
12.82 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1
7
Show member pathways
12.78 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1 HLA-C
8
Show member pathways
12.77 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1 HLA-C
9
Show member pathways
12.76 HLA-C HLA-B HLA-A CX3CL1
10 12.7 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1 HLA-C
11
Show member pathways
12.59 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1
12
Show member pathways
12.56 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1
13
Show member pathways
12.42 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1 HLA-C
14
Show member pathways
12.39 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1
15
Show member pathways
12.35 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1
16
Show member pathways
12.27 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1
17 12.24 HLA-C HLA-B HLA-A
18 12.24 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1
19
Show member pathways
12.22 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1
20 12.2 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1 HLA-C
21 12.14 HLA-C HLA-B HLA-A
22 12.06 HLA-C HLA-B HLA-A CD1A
23 12.02 HLA-C HLA-B HLA-A
24
Show member pathways
11.99 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1
25 11.96 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1
26 11.95 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1
27 11.9 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1
28 11.88 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1
29 11.74 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1
30 11.74 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1 HLA-C
31
Show member pathways
11.73 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1
32 11.7 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1 CD1E
33 11.4 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1 HLA-C
34 11.19 HLA-C HLA-B HLA-A

GO Terms for Pityriasis Rosea

Cellular components related to Pityriasis Rosea according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016020 10.32 HLA-DRB5 HLA-DRB3 HLA-DRB1 HLA-DQB1 HLA-C HLA-B
2 integral component of membrane GO:0016021 10.26 HLA-DRB5 HLA-DRB1 HLA-DQB1 HLA-C HLA-B HLA-A
3 plasma membrane GO:0005886 10.22 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1 HLA-C
4 Golgi apparatus GO:0005794 10.06 HLA-DRB5 HLA-DRB1 HLA-C HLA-B HLA-A CD1E
5 integral component of plasma membrane GO:0005887 10.05 HLA-DRB3 HLA-DRB1 HLA-C HLA-B HLA-A CD1E
6 endoplasmic reticulum membrane GO:0005789 10 HLA-DRB5 HLA-DRB1 HLA-C HLA-B HLA-A
7 endosome GO:0005768 9.97 HLA-DRB5 HLA-DRB1 HLA-DQB1 CD1E CD1A
8 cell surface GO:0009986 9.93 HLA-DRB1 HLA-C HLA-B HLA-A CX3CL1
9 Golgi membrane GO:0000139 9.91 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1 HLA-C
10 lysosome GO:0005764 9.89 HLA-DRB5 HLA-DRB1 HLA-DQB1 CD1E
11 lysosomal membrane GO:0005765 9.88 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1
12 endosome membrane GO:0010008 9.86 HLA-DRB5 HLA-DRB1 HLA-DQB1 CD1A
13 trans-Golgi network membrane GO:0032588 9.83 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1
14 late endosome membrane GO:0031902 9.8 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1
15 endocytic vesicle membrane GO:0030666 9.8 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1
16 early endosome membrane GO:0031901 9.79 HLA-C HLA-B HLA-A
17 transport vesicle membrane GO:0030658 9.77 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1
18 recycling endosome membrane GO:0055038 9.74 HLA-C HLA-B HLA-A
19 phagocytic vesicle membrane GO:0030670 9.72 HLA-C HLA-B HLA-A
20 clathrin-coated endocytic vesicle membrane GO:0030669 9.72 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1
21 MHC class I protein complex GO:0042612 9.63 HLA-C HLA-B HLA-A
22 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.56 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1 HLA-C
23 MHC class II protein complex GO:0042613 9.55 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1
24 ER to Golgi transport vesicle membrane GO:0012507 9.23 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1 HLA-C

Biological processes related to Pityriasis Rosea according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 10.01 HLA-DRB5 HLA-DRB1 HLA-DQB1 HLA-C HLA-B HLA-A
2 immune response GO:0006955 9.91 HLA-DRB5 HLA-DRB1 HLA-DQB1 HLA-C HLA-B HLA-A
3 regulation of immune response GO:0050776 9.88 HLA-C HLA-B HLA-A CD1A
4 T cell receptor signaling pathway GO:0050852 9.85 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1 HLA-A
5 antigen processing and presentation of exogenous peptide antigen via MHC class II GO:0019886 9.83 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1
6 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent GO:0002479 9.79 HLA-C HLA-B HLA-A
7 type I interferon signaling pathway GO:0060337 9.77 HLA-C HLA-B HLA-A
8 positive regulation of T cell mediated cytotoxicity GO:0001916 9.72 HLA-DRB1 HLA-B HLA-A CD1E CD1A
9 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.7 HLA-C HLA-B HLA-A
10 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.69 HLA-DRB5 HLA-DRB1 HLA-DQB1
11 detection of bacterium GO:0016045 9.67 HLA-DRB1 HLA-B HLA-A
12 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.65 HLA-C HLA-B HLA-A
13 antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent GO:0002486 9.63 HLA-C HLA-B HLA-A
14 antigen processing and presentation GO:0019882 9.63 HLA-DRB5 HLA-DRB1 HLA-DQB1 HLA-C HLA-B HLA-A
15 antigen processing and presentation, exogenous lipid antigen via MHC class Ib GO:0048007 9.62 CD1E CD1A
16 protection from natural killer cell mediated cytotoxicity GO:0042270 9.61 HLA-B HLA-A
17 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.6 HLA-DRB1 HLA-DQB1
18 antigen processing and presentation, endogenous lipid antigen via MHC class Ib GO:0048006 9.58 CD1E CD1A
19 positive regulation of CD4-positive, alpha-beta T cell activation GO:2000516 9.57 HLA-DRB3 HLA-DRB1
20 positive regulation of T cell mediated immune response to tumor cell GO:0002842 9.56 HLA-DRB3 HLA-DRB1
21 interferon-gamma-mediated signaling pathway GO:0060333 9.56 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1 HLA-C
22 myeloid dendritic cell antigen processing and presentation GO:0002469 9.55 HLA-DRB3 HLA-DRB1
23 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 9.54 HLA-DRB1 HLA-DQB1
24 adaptive immune response GO:0002250 9.32 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1 HLA-C

Molecular functions related to Pityriasis Rosea according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 T cell receptor binding GO:0042608 9.4 HLA-DRB1 HLA-A
2 lipopeptide binding GO:0071723 9.37 CD1E CD1A
3 MHC class II receptor activity GO:0032395 9.33 HLA-DRB3 HLA-DRB1 HLA-DQB1
4 exogenous lipid antigen binding GO:0030884 9.32 CD1E CD1A
5 endogenous lipid antigen binding GO:0030883 9.26 CD1E CD1A
6 peptide antigen binding GO:0042605 9.17 HLA-DRB5 HLA-DRB3 HLA-DRB1 HLA-DQB1 HLA-C HLA-B
7 TAP binding GO:0046977 9.13 HLA-C HLA-B HLA-A

Sources for Pityriasis Rosea

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....